At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100%
Monotherapy has been generally well-tolerated at RDEs
Promising combination potential, including no DLTs, encouraging safety data, and clearance of first dose escalation combination cohort of ERAS-0015 (16 mg) with approved commercial dose of panitumumab
Additional ERAS-0015 monotherapy and combination data expected H1 2027, including panitumumab combination data
Company plans to initiate a potentially registration-enabling trial in lung cancer in H1 2027, a Phase 3 trial in pancreatic cancer in 2027, and an additional Phase 3 trial in lung cancer in H2 2027 to H1 2028
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced updated preliminary Phase 1 data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. The Company also announced clinical development plans for the ERAS-0015 program, including potentially registration-enabling trials in lung and pancreatic cancers.
Updated preliminary data from Erasca's ongoing AURORAS-1 Phase 1 trial in the U.S. builds on the Company's April 2026 announcement, with additional patients and longer follow-up.
"We believe the continued notable responses in patients with pancreatic cancer in the U.S., together with the encouraging data in lung cancer and early signal in combination with panitumumab in metastatic colorectal cancer that we have seen in Phase 1, underscore the broad potential of ERAS-0015 to become a foundational therapy for multiple RAS-mutant solid tumors," said Jonathan E. Lim, M.D., Erasca's chairman, CEO, and co-founder. "We look forward to additional preliminary monotherapy and combination data expected in the first half of 2027. We believe that we are well positioned to execute our robust clinical development plan and transition into Phase 3 development."
Encouraging Monotherapy Responses Observed in Second Line or Greater (2L+) KRAS G12X Pancreatic Ductal Adenocarcinoma (PDAC)1
57% uORR8wk (N=7) at recommended dose for expansion (RDE) of 32 mg QD2
Across doses, all patients with either confirmed or unconfirmed responses remained on treatment
At RDE of 32 mg QD, 6 of 7 enrolled patients remained on treatment; at RDE of 24 mg QD, 6 of 8 enrolled patients remained on treatment